Latest studies
- RecruitingPhase III
A study of the anti-inflammatory medication colchicine for people with blocked arteries of the legs
Peripheral arterial disease (PAD) causes narrowed blood vessels in the legs. This clinical trial is testing whether an anti-inflammatory tablet called colchicine can help protect arteries and reduce the risk of serious complications, such as heart attacks, strokes, and leg amputations, in people living with PAD.
Peripheral artery diseaseArgentina - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
Type 2 Diabetes MellitusArgentina - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
Obesity or OverweightType 2 Diabetes MellitusArgentina - RecruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
Type 2 Diabetes MellitusArgentina - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
Obesity or OverweightArgentina - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaArgentina - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaArgentina - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Argentina - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Argentina - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseArgentina - RecruitingPhase III
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis
This clinical trial is testing a new medicine called DMX-200 for focal segmental glomerulosclerosis (FSGS), a rare kidney condition. Researchers want to see if adding DMX-200 to standard blood pressure medication helps protect kidney filters, reduces protein leaking into the urine, and slows down kidney damage better than a dummy pill.
Focal segmental glomerulosclerosisArgentina - RecruitingPHASE3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
This study is testing a new medicine called AZD6234 for adults who are overweight or have obesity and other health issues, including some with type 2 diabetes. It aims to see if adding AZD6234 to their current weight management medicines helps them lose more weight safely.
Obesity or OverweightWeight-Related ComorbidityWith/Without Diabetes Mellitus, Type 2Argentina - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study is testing a new drug (INCA33890) alongside standard chemotherapy and another medicine (bevacizumab) for advanced bowel cancer that has spread. It aims to see if adding INCA33890 is safe and helps people live longer and feel better.
CRC (Colorectal Cancer)Argentina - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
Biliary Tract CancerArgentina - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseArgentina - RecruitingPHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.
Alzheimer DiseaseAgitationArgentina - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaArgentina - RecruitingPHASE3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
This study is looking into a new medication called Eloralintide for people who are overweight or have obesity but don't have type 2 diabetes. It aims to see how well it works and if it's safe to help with weight management.
ObesityOverweightArgentina - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionArgentina - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerArgentina - Recruiting
Pompe Disease Registry Protocol
This registry tracks people with Pompe disease globally. It helps us understand the condition better, how it changes over time, and the effects of treatments. The goal is to improve care for everyone with Pompe disease.
Glycogen Storage Disease Type IIPompe DiseaseArgentina - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyIgANArgentina - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Gastric Cancer, AdenocarcinomaGastroesophageal Junction AdenocarcinomaArgentina - Active not recruitingPHASE3
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This study compares two treatments, ripretinib and sunitinib, for advanced GIST (a type of cancer) in patients who have already been treated with imatinib. It aims to see which treatment works best.
Gastrointestinal Stromal TumorsArgentina - Active not recruitingPHASE3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This study is comparing two ways of giving a medicine called amivantamab for advanced lung cancer. One is through a drip, and the other is a new injection under the skin. We want to see if the injection is easier and quicker for patients.
Advanced or Metastatic Non-small Cell Lung CancerArgentina - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaArgentina - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
Multiple MyelomaArgentina - Active not recruitingPHASE3
A Study of Zigakibart in Adults With IgA Nephropathy
This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).
IgA NephropathyImmunoglobulin A NephropathyArgentina - Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Fabry disease over time, including pregnant women. It helps doctors better understand the disease and improve care, without giving any new treatments. It's about observing, not experimenting.
Fabry DiseaseArgentina - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
Non-small Cell Lung CancerArgentina - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
Non-Small Cell Lung CancerArgentina - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerArgentina - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
Heart FailureArgentina - Active not recruitingPHASE3
Atrasentan in Patients With IgA Nephropathy
This study is testing a new medicine, atrasentan, for people with a kidney disease called IgA nephropathy. It compares atrasentan to a dummy pill (placebo) to see if it can slow down kidney damage and improve kidney function.
IgA NephropathyImmunoglobulin A NephropathyArgentina - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Argentina - Active not recruitingPHASE3
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
This study is testing a new medicine, ianalumab, for people with active Sjögren's syndrome. Researchers want to see if it's safe and helps improve symptoms. Participants will receive either the new medicine or a dummy medicine called a placebo.
Sjogren SyndromeArgentina - Active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseArgentina - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
Large B-Cell LymphomaArgentina - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
Extensive-Stage Small Cell Lung CancerArgentina - Active not recruitingPHASE3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study looks at a new medicine, BI 690517, combined with empagliflozin, for adults with chronic kidney disease. It aims to see if this combination can help slow down kidney disease progression and protect the heart, for people with and without type 2 diabetes.
Kidney Disease, ChronicArgentina - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCArgentina - Active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
This study is testing a new medication called donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow memory and thinking problems. It's a key step in understanding potential new treatments for this condition.
Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesArgentina - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
Carcinoma, Non-Small-Cell LungArgentina - Active not recruitingPHASE2
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
This study is looking into a new treatment called sotatercept for pulmonary arterial hypertension (PAH). It's an extension of a previous study. The main aim is to see if sotatercept, given in doses based on weight groups, is safe and can be tolerated by people with PAH over a longer time.
Pulmonary Arterial HypertensionArgentina - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
Breast NeoplasmsArgentina - RecruitingPHASE3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
This study is looking into the long-term safety of a new medicine called dazodalibep for people with Sjögren's Syndrome. It involves individuals who have already taken part in previous studies of this medicine.
Sjögren's SyndromeArgentina - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
Non-small Cell Lung CancerArgentina - Active not recruitingPHASE3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
This study is looking at a new medicine called deucravacitinib for people with active psoriatic arthritis who haven't tried certain other strong medicines for their condition before. It aims to see how well it works and if it's safe.
Psoriatic ArthritisArgentina - RecruitingPHASE3
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
This study looks at a new combination medicine for people with long-term kidney disease (CKD stages 3b and 4). It compares a new drug (balcinrenone/dapagliflozin) with an existing one (dapagliflozin) to see if it can slow down kidney disease and reduce heart problems, while being safe.
Renal Insufficiency, ChronicArgentina - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesArgentina